Search RGEN
REPLIGEN CORP
Nasdaq · CIK 730272
Last close181.7
Daily change+4.47 (2.52%)
10 Years gain+499.67%
Dividends TTM0
Dividend yield0.00%
Fundamental Analysis
RGEN · STANDARD
SIC 2836 · Biological Products, (No Diagnostic Substances) · Fiscal year end 1231
Fundamental
60.2Momentum
n/aAcceleration
n/aConfidence
63.0Annual Revenue8
Quarterly Revenue39
Annual CFO14
Balance SheetMissing
RankingLimited
Score Breakdown
Growth25.0 / 25
Quality17.2 / 25
Capital Efficiency0.0 / 20
Balance Sheet15.0 / 15
Shareholder Economics0.0 / 10
Forward Indicators0.0 / 5
Signals
No positive signals calculated.
Key Metrics
Revenue Growth TTM40.84%OK
Revenue CAGR 3Y30.5%OK
Gross Marginn/aMISSING
Operating Marginn/aMISSING
FCF Marginn/aMISSING
FCF Growthn/aINSUFFICIENT_HISTORY
ROICn/aMISSING
Incremental Operating Margin 3Yn/aNOT_MEANINGFUL
Net Debt / CFOn/aNOT_MEANINGFUL
Diluted Share Growth 1Yn/aINSUFFICIENT_HISTORY
SBC / Revenuen/aMISSING
SBC / FCFn/aNOT_MEANINGFUL
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 FY Dec 31, 2025 | n/a | $399.85M | $55.17M | $117.42M | $93.90M | n/a | n/a | n/a | 2.39% | 56,561 |
| 2025 FY Dec 31, 2024 | n/a | $271.45M | -$35.11M | $175.39M | $149.72M | n/a | n/a | n/a | -1.88% | 55,937 |
| 2025 FY Dec 31, 2023 | n/a | $309.01M | $47.70M | $113.92M | $77.70M | n/a | n/a | n/a | 2.38% | 56,377 |
| 2024 FY Dec 31, 2022 | n/a | $484.44M | $224.67M | $172.08M | $87.25M | n/a | n/a | n/a | 15.05% | 57,455 |
| 2023 FY Dec 31, 2021 | n/a | $385.39M | $167.25M | $119.02M | $51.93M | n/a | n/a | n/a | 14.27% | 57,264 |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $159.60M | sum latest 4 fiscal quarters Revenue | OK | 0001193125-18-054262, 0001193125-17-338561 |
| Revenue Growth TTM | 40.84% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0001193125-18-054262, 0001193125-17-338561 |
| Revenue CAGR 3Y | 30.5% | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | OK | 0001193125-18-054262 |
| Revenue CAGR 5Y | 17.8% | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | OK | 0001193125-18-054262 |
| Gross Profit CAGR 3Y | n/a | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | INSUFFICIENT_HISTORY | derived |
| Operating Income Growth | n/a | OperatingIncome_current / OperatingIncome_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Net Debt / CFO | n/a | Net Debt / CFO | NOT_MEANINGFUL | derived |
| Current Ratio | 12.22x | Current Assets / Current Liabilities | OK | derived |
| SBC / FCF | n/a | SBC / FCF | NOT_MEANINGFUL | derived |
| Dividend Payout Ratio | n/a | Cash dividends paid / Net income | NOT_MEANINGFUL | derived |
| Diluted EPS TTM | n/a | Net income TTM / Diluted shares | NOT_MEANINGFUL | derived |
| Gross Margin Delta 1Y | n/a | GrossMargin_current - GrossMargin_prior_year | INSUFFICIENT_HISTORY | derived |
| Gross Margin Delta 3Y | n/a | GrossMargin_current - GrossMargin_3Y_ago | INSUFFICIENT_HISTORY | derived |